Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.
Xu. X. (Suzhou Miracpharma); Process for the preparation of acalabrutinib. CN 107056786 (2017)
No Data
Barf, TA.; Jans, CGM; De Man, APA; Oubrie, AA; Raaijmakers, HCA; Rewinkel, JBM;Sterrenburg, JG; Wijkmans, JCHM. Preparation of imidazopyrazinylbenzamide derivatives and analogs for use as Btk inhibitors. WO 2013010868 (2013).
Anon. Process for preparation of 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide. IP.com Journal. Volume 19. Issue 4B. Pages 1-4. 2019.
Wang, Peng; Li, Pixu; Gu, Xiangyong; Ge, Yadong; Wang, Zhong; Gao, Feng; Du, Qiangqiang. Processes for the preparation of acalabrutinib. WO 2019090269. 2019.
Zheng, Xuchun; Zhang, Yiping; Fu, Chenchen. Synthesis method of acalabrutinib and its intermediate. Assignee Hangzhou Cheminspire Technologies Co., Ltd. CN 108250186. 2018.
Hamdy, Ahmed; Rothbaum, Wayne; Izumi, Raquel; Lannutti, Brian; Covey, Todd; Ulrich, Roger; Johnson, Dave; Barf, Tjeerd; Kaptein, Allard. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, a PD-1 inhibitor and/or a PD-L1 inhibitor. Assignee Acerta Pharma B.V., Neth. WO 2016024228. 2016.
Wu, Xueping; Chu, Yijie; Chen, Yao; Wang, Min. Method for preparing acalabrutinib as anti-leukemia drug using 4-aldehyde-N-2-pyridine-benzamide. Assignee Anqing CHICO Pharmaceutical Co., Ltd. CN 109020977. 2018.
Bodhuri, Prabhudas; Gorin, Boris; Green, Melanie R. A.; Weeratunga, Gamimi. Processes for the preparation of Acalabrutinib and intermediates thereof. Assignee Apotex Inc.WO 2018191815. 2018.
